Annual ROE
-46.47%
+107.83%+69.88%
31 March 2024
Summary:
VistaGen Therapeutics annual return on equity is currently -46.47%, with the most recent change of +107.83% (+69.88%) on 31 March 2024. During the last 3 years, it has fallen by -4.88% (-11.73%). VTGN annual ROE is now -100.21% below its all-time high of 22.00 thousand%, reached on 31 December 2009.VTGN ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
-42.00%
+1.12%+2.60%
30 September 2024
Summary:
VistaGen Therapeutics quarterly return on equity is currently -42.00%, with the most recent change of +1.12% (+2.60%) on 30 September 2024. Over the past year, it has increased by +127.19% (+75.18%). VTGN quarterly ROE is now -100.71% below its all-time high of 5933.33%, reached on 31 December 2010.VTGN Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VTGN ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +69.9% | +75.2% |
| 3 y3 years | -11.7% | +6.6% |
| 5 y5 years | +86.8% | +96.3% |
VTGN ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -11.7% | +69.9% | at high | +79.1% |
| 5 y | 5 years | -11.7% | +98.5% | -107.0% | +99.8% |
| alltime | all time | -100.2% | +98.5% | -100.7% | +99.9% |
VistaGen Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -42.00%(-2.6%) |
| June 2024 | - | -43.12%(-14.2%) |
| Mar 2024 | -46.47%(-69.9%) | -50.25%(-37.8%) |
| Dec 2023 | - | -80.76%(-52.3%) |
| Sept 2023 | - | -169.19%(-15.9%) |
| June 2023 | - | -201.17%(+17.6%) |
| Mar 2023 | -154.30%(+153.1%) | -171.11%(+29.5%) |
| Dec 2022 | - | -132.16%(+23.4%) |
| Sept 2022 | - | -107.11%(+27.9%) |
| June 2022 | - | -83.74%(+41.3%) |
| Mar 2022 | -60.96%(+46.6%) | -59.27%(+37.4%) |
| Dec 2021 | - | -43.15%(-4.1%) |
| Sept 2021 | - | -44.98%(+7.7%) |
| June 2021 | - | -41.76%(-16.8%) |
| Mar 2021 | -41.59%(-98.7%) | -50.19%(-46.0%) |
| Dec 2020 | - | -92.99%(-119.6%) |
| Sept 2020 | - | 473.86%(+41.1%) |
| June 2020 | - | 335.91%(-44.1%) |
| Mar 2020 | -3087.23%(+778.3%) | 600.90%(-103.5%) |
| Dec 2019 | - | -17.37 K%(+1425.3%) |
| Sept 2019 | - | -1138.60%(+50.8%) |
| June 2019 | - | -755.05%(+40.6%) |
| Mar 2019 | -351.49%(-7.7%) | -537.00%(+22.1%) |
| Dec 2018 | - | -439.85%(+6.7%) |
| Sept 2018 | - | -412.28%(-8.3%) |
| June 2018 | - | -449.58%(-2.7%) |
| Mar 2018 | -380.91%(-77.1%) | -462.27%(-19.3%) |
| Dec 2017 | - | -572.71%(-53.9%) |
| Sept 2017 | - | -1241.71%(+202.3%) |
| June 2017 | - | -410.74%(-16.1%) |
| Mar 2017 | -1665.39% | -489.44%(-50.1%) |
| Dec 2016 | - | -980.82%(-45.7%) |
| Sept 2016 | - | -1806.83%(-94.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2016 | - | -30.01 K%(-1492.8%) |
| Mar 2016 | 1586.07%(+2246.6%) | 2154.64%(+215.6%) |
| Dec 2015 | - | 682.67%(+65.4%) |
| Sept 2015 | - | 412.86%(+55.6%) |
| June 2015 | - | 265.41%(+239.7%) |
| Mar 2015 | 67.59%(+191.5%) | 78.14%(+30.4%) |
| Dec 2014 | - | 59.92%(+3.7%) |
| Sept 2014 | - | 57.79%(-1.4%) |
| June 2014 | - | 58.59%(+142.7%) |
| Mar 2014 | 23.19%(-77.4%) | 24.14%(-39.9%) |
| Dec 2013 | - | 40.17%(-53.8%) |
| Sept 2013 | - | 86.89%(-17.1%) |
| June 2013 | - | 104.86%(-27.1%) |
| Mar 2013 | 102.63%(-52.0%) | 143.90%(-14.3%) |
| Dec 2012 | - | 167.88%(-14.0%) |
| Sept 2012 | - | 195.15%(+6.9%) |
| June 2012 | - | 182.51%(-1.9%) |
| Mar 2012 | 213.99%(-76.2%) | 186.00%(+4.2%) |
| Dec 2011 | - | 178.53%(+50.8%) |
| Sept 2011 | - | 118.41%(-13.6%) |
| June 2011 | - | 136.98%(-97.0%) |
| Mar 2011 | - | 4560.00%(-23.1%) |
| Dec 2010 | 900.00%(-95.9%) | 5933.33%(-153.0%) |
| Sept 2010 | - | -11.20 K%(+747.4%) |
| June 2010 | - | -1321.74%(+4.3%) |
| Mar 2010 | - | -1266.67%(-55.9%) |
| Dec 2009 | 22.00 K%(<-9900.0%) | -2869.57%(+549.1%) |
| Sept 2009 | - | -442.11%(+46.7%) |
| June 2009 | - | -301.40%(-18.9%) |
| Mar 2009 | - | -371.60%(+8.9%) |
| Dec 2008 | -80.39% | -341.38%(-387.7%) |
| Sept 2008 | - | 118.64%(+2.9%) |
| June 2008 | - | 115.25%(-39.9%) |
| Mar 2008 | - | 191.67% |
FAQ
- What is VistaGen Therapeutics annual return on equity?
- What is the all time high annual ROE for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual ROE year-on-year change?
- What is VistaGen Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly ROE year-on-year change?
What is VistaGen Therapeutics annual return on equity?
The current annual ROE of VTGN is -46.47%
What is the all time high annual ROE for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual return on equity is 22.00 K%
What is VistaGen Therapeutics annual ROE year-on-year change?
Over the past year, VTGN annual return on equity has changed by +107.83% (+69.88%)
What is VistaGen Therapeutics quarterly return on equity?
The current quarterly ROE of VTGN is -42.00%
What is the all time high quarterly ROE for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly return on equity is 5933.33%
What is VistaGen Therapeutics quarterly ROE year-on-year change?
Over the past year, VTGN quarterly return on equity has changed by +127.19% (+75.18%)